Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Home workouts and protein shakes may help pancreatic cancer patients fight muscle loss

NCT ID NCT05356117

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a home-based resistance exercise program combined with protein supplements can help people with pancreatic cancer maintain muscle mass while on chemotherapy. About 45 participants will be assigned to one of three groups: exercise plus protein, exercise only, or gentle stretching. The main goal is to see if this approach is practical and well-tolerated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 45 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2022

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Non-metastatic pancreatic cancer patients initiating neoadjuvant chemotherapy. * Ability to understand and the willingness to sign a written informed consent document. * Over the age of 18 years; children under the age of 18 will be excluded due to rarity of disease. * Speak English or Spanish. * Able to provide physician clearance to participate in the exercise program. * Able to initiate a supervised exercise program (free from any cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity). * Currently participate in less than or equal to 60 minutes of structured moderate or vigorous exercise/week. * Does not smoke (no smoking during previous 12 months). * Willing to travel to DFCI for assessments. Exclusion Criteria: * Patients should not have any uncontrolled illness including ongoing or active infection, uncontrolled diabetes, hypertension or thyroid disease. * Patients may not be receiving any other investigational agents. * Patients with other active malignancies are ineligible for this study. * Patients with metastatic disease. * History of any musculoskeletal, cardiorespiratory or neurological diseases that preclude the participation in exercise. * Patients expected to receive other cancer directed treatments during the study and assessment period. * Participates in more than 60 minutes of structured moderate or vigorous exercise/week. * Currently smokes. * Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study. * Is unable to travel to DFCI for assessments. * Patients who are pregnant due to the unknown effects of exercise on the developing fetus.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.